CN1486743A - Chinese medicine injection and its production process - Google Patents
Chinese medicine injection and its production process Download PDFInfo
- Publication number
- CN1486743A CN1486743A CNA2003101033930A CN200310103393A CN1486743A CN 1486743 A CN1486743 A CN 1486743A CN A2003101033930 A CNA2003101033930 A CN A2003101033930A CN 200310103393 A CN200310103393 A CN 200310103393A CN 1486743 A CN1486743 A CN 1486743A
- Authority
- CN
- China
- Prior art keywords
- extract
- injection
- amount
- water
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 38
- 239000007924 injection Substances 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title description 5
- 241000222336 Ganoderma Species 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 208000019423 liver disease Diseases 0.000 claims abstract description 4
- 238000007670 refining Methods 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 239000007788 liquid Substances 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 26
- 239000010231 banlangen Substances 0.000 claims description 19
- 239000008215 water for injection Substances 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 238000004321 preservation Methods 0.000 claims description 10
- 230000027326 copulation Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 5
- 229960003321 baicalin Drugs 0.000 claims description 5
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 4
- 229940074393 chlorogenic acid Drugs 0.000 claims description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 4
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 7
- 238000000605 extraction Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010023126 Jaundice Diseases 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 241001662043 Icterus Species 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 102000003929 Transaminases Human genes 0.000 abstract 1
- 108090000340 Transaminases Proteins 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000006837 decompression Effects 0.000 description 10
- 238000004064 recycling Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008865 yin zhi huang Substances 0.000 description 4
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is one kind of Chinese medicine injection for treating hepatosis and its preparation process. The Chinese medicine injection is prepared with medicine materials including oriental wormwood, cape jasmine, isatis root, glossy ganoderma and skullcap root, and through extraction, refining, mixing, superfiltering, filtering and other steps. The present invention has the functions of eliminating icterus, lowering transaminase, strengthening immunological activity and protecting liver. It has high curative effect, fast action, no toxic side effect, medium cost and other advantages.
Description
Technical field
The present invention relates to a kind of injection and production technology thereof for the treatment of hepatopathy.
Technical background
Hepatitis is a kind of commonly encountered diseases, and one of its topmost infringement is hepatocellular destruction or disintegrate, and the result causes the rapid increase of Serum ALT and serum bilirubin (SB), impels hepatocyte conversely again over-burden the enzyme poisoning until infringement and each organ of whole body.Therefore reduce ALT and bilirubin and become the problem that the treatment hepatitis medicament mainly solves.But at present domestic medicine, particularly Chinese medicine generally all be oral administration solids such as tablet, capsule, these medicines all exist take effect slowly, the course of treatment problem such as length, price height, can not be that the patient is used well.
Summary of the invention:
The objective of the invention is to: a kind of production technology economical rationality, good effect, instant effect are provided, have no side effect, safe and reliable, moderate pure Chinese medicine injection, to overcome the deficiencies in the prior art.
The present invention is achieved in that
Through water extract-alcohol precipitation, the Herba Artemisiae Scopariae extract that obtains, Fructus Gardeniae extract, Radix Isatidis extract, Ganoderma extract and Radix Scutellariae extract are mixed with certain density intermediate A, B liquid, ultrafiltration with water for injection with medical material Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Isatidis, Ganoderma.According to intermediate A, B liquid assay, calculate the consumption that needs intermediate A liquid and B liquid, accurately measure A liquid and B liquid respectively, drop into Agitation Tank and mix.It is an amount of to add the injection water, regulates medicinal liquid pH7.2-7.9 with 10% sodium hydroxide.Add the injection water to dosing total amount (making every 1000ml contain Herba Artemisiae Scopariae extract 4g, Fructus Gardeniae extract 3g, Radix Isatidis extract 5g, Ganoderma extract 3.5g and Radix Scutellariae extract 22g), stir, the medicinal liquid fine straining is extremely clear and bright, embedding, and 115 ℃ of 45min sterilizations are promptly.
Production technology
One, extract: after getting the clean system of each medical material respectively, clean medical material is cut into slices or section according to different medical material character and character fragmentation.Get recipe quantity Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Isatidis, Ganoderma medicinal material coarse powder or sheet respectively, drop in the extraction pot of suitable size, water carries twice, merges decoction liquor, is evaporated to relative density and reaches each medical material kind requirement.Concentrated solution adds ethanol to the alcohol amount of containing respectively and reaches 60% and 80% to carry out precipitate with ethanol refining, reclaims ethanol, and it is an amount of to add water for injection, 115 ℃ of 45 minutes heat treatments, put cold, 2～10 ℃ of cold preservations.Radix Isatidis extract ammonia is heavy, filters, and filtrate is waved ammonia, uses Na
2CO
3Solution is regulated PH, 115 ℃ of 45 minutes heat treatments, put cold, 2～10 ℃ of cold preservations.Get cold preservation liquid, filter, detect certified products copulation material and use.Get recipe quantity Radix Scutellariae coarse powder, water carries twice, merges decoction liquor, filters, filtrate adds hydrochloric acid and regulates PH, insulation, cooling, leave standstill, the leaching precipitation adds the suitable quantity of water suspendible, add 40% sodium hydroxide and regulate PH, add an amount of ethanol again, filter, filtrate adds hydrochloric acid and regulates PH, heat tracing, leaching precipitation, after an amount of washing of ethanol, drying detects certified products copulation material and uses.
Radix Isatidis extract:
Get the clean medicine section of recipe quantity Radix Isatidis, drop into extraction pot, the decocting that adds certain multiple respectively boils twice.Collecting decoction, filter, after filtrate decompression is concentrated into relative density and is 1.2, add ethanol and make and contain the alcohol amount and reach 60%, airtight placement, filter, filtrate recycling ethanol, and to be evaporated to relative density be 1.20, after adding an amount of water for injection mixing, add strong aqua ammonia and transfer pH value to 8, behind the cold preservation certain hour, filter.Filtrate adds evanescence of heat ammonia, and it is an amount of to add the injection water, uses Na
2CO
3Solution is regulated PH=7, and 115 ℃ of heat treatments 45 minutes are put coldly, in 2～10 ℃ of cold preservations, filter, and filtrate is detected qualified back copulation material and used.
Fructus Gardeniae extract:
Get Fructus Gardeniae and be ground into coarse powder, the decocting that adds certain multiple respectively boils twice.Collecting decoction filters.After filtrate decompression is concentrated into relative density and is 1.2, add ethanol and make and contain the alcohol amount and reach 60%, airtight leaving standstill filters, and decompression filtrate recycling ethanol, and be concentrated into relative density 1.15 adds ethanol and makes and contain the alcohol amount and reach 80%, leaves standstill, and filters decompression filtrate recycling ethanol.Extractum adds the water for injection stirring and evenly mixing, and 115 ℃ of heat treatments 45 minutes filter, and filtrate is detected qualified back copulation material and used.
Ganoderma extract:
Get Ganoderma powder and be broken into coarse powder, the decocting that adds certain multiple respectively boils twice, merges the squeezing decocting liquid and filters.It is 1.05 that filtrate decompression is concentrated into relative density, adds ethanol and makes and contain the alcohol amount and reach 60%, leaves standstill, filter, decompression filtrate recycling ethanol, and concentrated relative density is 1.0, add ethanol and make and contain the alcohol amount and reach 80%, leave standstill, filter, decompression filtrate recycling ethanol, extractum adds an amount of stirring and evenly mixing of water for injection, sterilizes 45 minutes for 115 ℃, in 2～10 ℃ of cold preservations, filter, filtrate is detected qualified back copulation material and is used.
Herba Artemisiae Scopariae extract:
Get Herba Artemisiae Scopariae and clean, the decocting that adds certain multiple respectively boils twice, and collecting decoction filters.It is 1.2 that filtrate decompression is concentrated into relative density, adds ethanol and makes and contain the alcohol amount and reach 60%, leaves standstill, and filters, and decompression filtrate recycling ethanol, and to be concentrated into relative density be 1.15 adds ethanol and makes and contain the alcohol amount and reach 80%, leaves standstill, and filters.Decompression filtrate recycling ethanol, extractum add an amount of water for injection stirring and evenly mixing, sterilize 45 minutes for 115 ℃, and 2～10 ℃ of cold preservations are filtered, and filtrate is detected qualified back copulation material and used.
Radix Scutellariae extract:
Get Radix Scutellariae powder and be broken into coarse powder, the decocting that adds certain multiple respectively boils twice, merges decoction liquor, filters, filtrate adds hydrochloric acid and regulates PH1-2, insulation certain hour, cooling, leave standstill, the leaching precipitation adds the suitable quantity of water suspendible, add 40% sodium hydroxide and regulate PH7, add an amount of ethanol again, filter, filtrate adds hydrochloric acid and regulates PH1-2, heat tracing certain hour, leaching precipitation, after an amount of washing of ethanol, drying detects certified products copulation material and uses.
Two, intermediate preparation:
Divide the preparation of intermediate A liquid and B liquid.A liquid includes Radix Isatidis, Herba Artemisiae Scopariae, Ganoderma, Fructus Gardeniae extract; B liquid includes Radix Scutellariae extract.
The preparation of intermediate A liquid:
Press the requirement of each medicinal substances extract under each medicinal substances extract quality standard chemical examination data computation amount of preparation of soothing liver-QI.Inclining Radix Isatidis, Herba Artemisiae Scopariae, Ganoderma, the refining extracting solution mixing of Fructus Gardeniae, filters with suitable filter.Add an amount of water for injection, add the 0.1-0.25% active carbon and stir evenly, boil 30 minutes after, filtering decarbonization adds water for injection to the dosing amount, abundant mixing, 115 ℃ of sterilizations 45 minutes are put coldly, filter, with the ultrafilter ultrafiltration of certain molecular retention amount.Get filtrate and detect the rare adapted of qualified back friendship.
The preparation of intermediate B liquid:
Take by weighing Radix Scutellariae extract by the side, add an amount of suspendible of injection water, make dissolving, transfer PH=7.0-7.5, mixing with 10%NaOH solution.Add an amount of water for injection.Add the 0.1-0.25% active carbon and stir evenly, boil 30 minutes after, use the filter filtering decarbonization, add water for injection to the dosing amount, abundant mixing, 115 ℃ of sterilizations 45 minutes are put cold.With the ultrafilter ultrafiltration of certain molecular retention amount, hand over rare adapted behind the sample examination content of baicalin.
Three, preparation:
According to the consumption of intermediate A, B liquid assay calculating needs intermediate A liquid and B liquid, get A liquid and B liquid respectively, drop into Agitation Tank and mix.It is an amount of to add the injection water, regulates medicinal liquid pH7.2-7.9 with 10% sodium hydroxide.Adding injection water to dosing total amount [makes every 1000ml contain Herba Artemisiae Scopariae extract 4g, Fructus Gardeniae extract 3g, Radix Isatidis extract 5g, Ganoderma extract 3.5g and Radix Scutellariae extract 22g.Every 1ml contains Herba Artemisiae Scopariae extract with chlorogenic acid (C
16H
18O
9) meter, must not be less than 0.04mg; Contain Fructus Gardeniae extract with jasminoidin (C
17H
24O
10) meter, must not be less than 0.45mg.; Contain Radix Scutellariae extract with baicalin (C
21H
18O
11) meter, must not be less than 19.5mg.Contain total solid and should be 36.0～50.0mg], stir.After semi-finished product mensuration was qualified, the medicinal liquid fine straining was extremely clear and bright, embedding, and 115 ℃ of 45min sterilizations are promptly.
The present invention compared with prior art has following advantage:
One, can promote bile secretion, enzyme commentaries on classics reaction reduces rapidly and removes Serum ALT, AST and bilirubinic content, alleviates the hepatocyte burden, avoids hepatocyte further to damage, and alleviates the toxic reaction of whole body simultaneously, improves body function;
Two, can improve the liver blood circulation, promote the hepatocyte metabolism, especially improve hepatocellular oxygen-resistant ability, strengthen autoimmunity.The experiment proved that the hepatocyte that the present invention brings out CCL4 and galactose damages significant inhibitory effect, particularly hepatocellular degeneration, necrosis and inflammatory cell infiltration is had significantly to alleviate effect.The effective ingredient such as Fructus Gardeniae that the present invention contained also have blocking-up or reverse the Fibrotic effect of hepatocyte.
Three, can obviously improve body's immunological function, especially active ingredient such as Ganoderma is by regulating and improving central nervous system unify neuro excitement and inhibition, thereby strengthen the regulating action of a neural body fluid, the human body immunity improving system, particularly the activity of cellular immunization and humoral immunization is resisted the further infringement of virus.Reach the purpose of improving clinical symptoms, accelerating sick clear recovery.Tissue slice confirms, its total white blood cells and lymphocyte number are escaped by luck significantly to be increased, especially improve the positive percentage of investigation mission outside the city or town blood lymphocytes, immunoreation due to the hydrocortisone there is inhibitory action, but and the antivirus action of inducement interferon, show that the present invention is many-sided in increasing hectare body's immunity;
Four, medicine such as Radix Isatidis, Radix Scutellariae active ingredient has the effect that suppresses virus and toxic reaction thereof, and is improving Abwehrkraft des Koepers, promoting under the multiple influence of immunocompetence, inducement interferon, and common performance suppresses virus, the effect that alleviates hepatocellular damage; The present invention improves significantly to the myocardial ischemia that is subjected to virus infringement, especially to improving myocardial hypoxia tolerance remarkable enhancing is arranged, thereby heart tonifying, diuresis, is beneficial to jaundice eliminating; And by regulating neuro function reduction elevated blood pressure; Alleviate portal vein pressure, improve liver blood and follow; The present invention also has stronger inhibitory action to cell infections such as golden Portugal bacterium, Bacillus typhi, escherichia coli.
Attached: soothing liver-QI injection pharmacodynamic experiment data
The influence of table 1 couple CCl4 acute liver damage mice serum AST, ALT (X ± S)
-
| Group | Dosage (ml/10g) | Example number (only) | ????AST(Iu/L) | ????ALT(Iu/L) |
| Matched group model group Yinzhihuang Injection soothing liver-QI injection | ????- ????- ????0.05 ????0.025 ????0.05 ????0.1 | ????10 ????10 ????10 ????10 ????10 ????10 | ??106.19±12.74 ??811.59±492.31 ??157.15±52.70 **??220.31±78.94 **??112.58±15.82 **??114.58±13.28 ** | ??57.11±14.85 ??445.88±279.68 ??121.85±70.82 **??198.53±72.31 **??68.47±20.74 **??63.26±16.51 ** |
Annotate: compare with model group
*＜0.05,
*＜0.01 (down together).
Table 2 couple CCl
4The comparison that acute liver damage mice histopathology changes
| Group | Dosage (ml/10g) | Example number (only) | Hepatocellular degeneration hepatic necrosis cell infiltration+++ ++++ ++ ++++ ++ +++ |
| Matched group model group Yinzhihuang Injection soothing liver-QI injection | ????- ????- ????0.05 ????0.025 ????0.05 ????0.1 | ????10 ????10 ????10 ????10 ????10 ????10 | ?-????-??????-????-????-????-??????-????-????- ?3????2??????5????4????2????4??????2????2????1 ?4????3??????2????5????2????1??????3????0????0 ?4????3??????3????3????5????2??????2????3????0 ?6????2??????1????4????2????1??????4????0????0 ?3????3??????2????5????3????1??????2????1????0 |
The influence of table 3 pair bacillus calmette-guerin vaccine, lipopolysaccharide-induced hepatic injury mice serum AST, ALT (X ± S) _
| Group | Dosage (every kg body weight) | Example number (only) | ????ALT(Iu/L) | ????SB(Iu/L) |
| Matched group model group cyclophosphamide soothing liver-QI injection | ????- ????- ????30mg ????2.5ml ????5ml ????10ml | ????9 ????10 ????10 ????10 ????9 ????10 | 40.22±7.08 292.10±47.59 91.85±28.10 155.16±42.3 **147.82±40.02 **122.84±38.38 ** | ?76.93±8.67 ?431.71±81.29 ?193.02±46.38 ?296.77±75.38 **?275.42±55.30 **?236.69±64.03 ** |
Annotate: respectively have an animal serum amount few in matched group, the soothing liver-QI injection in the dosage group, fail to do the biochemical indicator inspection.
The comparison of table 4 pair immunologic liver injury mice pathological change
| Group | Dosage (every kg body weight) | Example number (only) | Portal area cell infiltration number of animals | The hepatic necrosis number of animals | The P value |
| Matched group model group cyclophosphamide soothing liver-QI injection | ????- ????- ????30mg ????2.5ml ????5ml ????10ml | ????10 ????10 ????10 ????10 ????10 ????10 | ????0 ????10 ????10 ????10 ????10 ????10 | ????0 ????9 ????1 ????4 ????2 ????2 | ＜0.01 ＜0.01 ＜0.01 ＜0.01 |
The protective effect of rats'liver damage due to the table 5 pair phenyl isothiocyanate (X ± S)-
| Group | Dosage (m/110g) | Example number (only) | ??ALT(Iu/L) | ????SB(umol/L) |
| Matched group model group Yinzhihuang Injection soothing liver-QI injection | ????- ????- ????0.4 ????0.2 ????0.4 ????0.8 | ????10 ????9 ????9 ????9 ????9 ????10 | ?63.19±11.91 ?112.17±40.13 ?62.82±28.45 ?75.42±18.75 *?64.51±19.91 **?65.73±16.51 ** | ????3.82±1.21 ????10.25±2.68 ????5.30±2.56 ????6.57±1.41 *????6.34±2.86 *????5.29±1.20 ** |
Table 6 soothing liver-QI injection is to the influence of big cowardly hidropoiesis (X ± S)
-
| Group | Dosage (ml/10g) | Example number (only) | Bile flow (ml/30min) | ||||
| Before the administration | After the administration | ||||||
| ????30 | ????60 | ????90 | ????120 | ||||
| Matched group Yinzhihuang Injection soothing liver-QI injection | ????- ????0.4 ????0.2 ????0.4 ????0.8 | ???12 ???12 ???12 ???11 ???12 | ?0.37±0.09 ?0.36±0.06 ?0.38±0.06 ?0.37±0.07 ?0.39±0.09 | ?0.22±0.08 ?0.50±0.10 ?0.41±0.08 **?0.48±0.11 **?0.55±0.11 ** | ?0.34±0.07 ?0.51±0.10 ?0.50±0.11 **?0.52±0.10 **?0.58±0.12 ** | ??0.39±0.09 ??0.54±0.11 ??0.49±0.08 *??0.55±0.10 **??0.59±0.11 ** | ?0.37±0.07 ?0.44±0.07 ?0.41±0.09 ?0.45±0.09 *?0.50±0.08 ** |
Annotate: compare with matched group
*＜0.05,
*＜0.01.
The influence of table 7 pair mice reticuloendothelial system phagocytic function (X ± SD)
=
| Group | Dosage (every kg body weight) | Example number (only) | The K value | The P value |
| Matched group cyclophosphamide levamisole soothing liver-QI injection | ????- ????30mg ????25mg ????2.5ml ????5ml ????10ml | ????10 ????10 ????10 ????10 ????10 ????10 | ??0.015±0.004 ??0.008±0.002 ??0.022±0.005 ??0.011±0.003 ??0.012±0.004 ??0.014±0.005 | ????＜0.01 ????＜0.05 ????＜0.05 ????＜0.01 |
The influence of table 8 pair hemolytic antibody (X ± SD)
-
| Group | Dosage (every kg body weight) | Example number (only) | ????HC 50 | The P value |
| Matched group cyclophosphamide levamisole soothing liver-QI injection | ????- ????30mg ????25mg ????2.5ml ????5ml ????10ml | ????10 ????10 ????10 ????10 ????10 ????10 | ??290.6±35.6 ??73.0±28.6 ??359.4±36.7 ??105.4±35.9 ??123.0±35.1 ??171.6±31.2 | ????＜0.05 ????＜0.01 ????＜0.01 |
The influence of table 9 pair mice delayed hypersensitive reaction (X ± SD)
-
| Group | Dosage (every kg body weight) | Example number (only) | Swollen pus degree | The P value |
| Matched group cyclophosphamide levamisole soothing liver-QI injection | ????- ????30mg ????25mg ????2.5ml ????5ml ????10ml | ????10 ????10 ????10 ????10 ????10 ????10 | ????0.26±0.04 ????0.10±0.03 ????0.18±0.04 ????0.13±0.03 ????0.15±0.05 ????0.16±0.05 | ????＜0.01 ????＜0.05 ????＜0.05 ????＜0.01 |
The specific embodiment:
Embodiments of the invention: to produce the 1000ml injection is example.According to the analysis data of intermediate A liquid, B liquid, get the intermediate A liquid and the B liquid of some respectively, drop into Agitation Tank and mix.It is an amount of to add the injection water, regulates medicinal liquid pH7.2-7.9 with 10% sodium hydroxide, adds to inject water and make to 1000ml[and contain Herba Artemisiae Scopariae extract 4g, Fructus Gardeniae extract 3g, Radix Isatidis extract 5g, Ganoderma extract 3.5g and Radix Scutellariae extract 22g.Every 1ml contains Herba Artemisiae Scopariae extract with chlorogenic acid (C
16H
18O
9) meter, must not be less than 0.04mg; Contain Fructus Gardeniae extract with jasminoidin (C
17H
24O
10) meter, must not be less than 0.45mg.; Contain Radix Scutellariae extract with baicalin (C
21H
18O
11) meter, must not be less than 19.5mg.Contain total solid and should be 36.0～50.0mg], stir.After semi-finished product mensuration was qualified, the medicinal liquid fine straining was extremely clear and bright, embedding, and 115 ℃ of 45min sterilizations, lamp inspection, labeling, packings get product.
[notes] easypro liver injection pharmacodynamics test report (in full) See Attachment 1
The liver injection medicine clinical experiment report (in full) that relaxes sees Appendix two
The liver injection pharmacodynamics test report (summary) of relaxing sees Appendix three
The liver injection medicine clinical experiment report (summary) that relaxes sees Appendix four
Claims (2)
1, a kind of Chinese medicine injection for the treatment of hepatopathy is characterized in that: it is formulated with Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Isatidis, Ganoderma and radix scutellariae medicinal materials, it is characterized in that: the consumption of the every 1000ml of said components is, Herba Artemisiae Scopariae extract 4g, Fructus Gardeniae extract 3g, Radix Isatidis extract 5g, Ganoderma extract 3.5g and Radix Scutellariae extract 22g, every 1ml contain Herba Artemisiae Scopariae extract with chlorogenic acid (C
16H
18O
9) meter, must not be less than 0.04mg; Contain Fructus Gardeniae extract with jasminoidin (C
17H
24O
10) meter, must not be less than 0.45mg.; Contain Radix Scutellariae extract with baicalin (C
21H
18O
11) meter, must not be less than 19.5mg, contain total solid and should be 36.0～50.0mg.
2, a kind of its preparation of Chinese medicine injection for the treatment of hepatopathy is characterised in that: get recipe quantity Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Isatidis, Ganoderma medicinal material coarse powder or sheet respectively, carry out water and carry that to reach 60% and 80% precipitate with ethanol respectively refining with containing the alcohol amount for twice, extractum adds an amount of water for injection, and to carry out water precipitating or ammonia heavy, after Ganoderma, Fructus Gardeniae, Herba Artemisiae Scopariae extract add water, and 115 ℃ of 45 minutes heat treatments, put cold, in 2～10 ℃ of cold preservations, after Radix Isatidis extract ammonia is heavy, filter, filtrate is waved ammonia, uses Na
2CO
3Solution is regulated PH, and 115 ℃ of 45 minutes heat treatments are put cold, in 2～10 ℃ of cold preservations, get cold preservation liquid, filter, preparation intermediate A liquid is got recipe quantity Radix Scutellariae coarse powder, and water is carried twice, merge decoction liquor, filter, filtrate adds hydrochloric acid and regulates PH, insulation, cooling is left standstill, the leaching precipitation adds the suitable quantity of water suspendible, adds 40% sodium hydroxide and regulates PH, add an amount of ethanol again, filter, filtrate adds hydrochloric acid and regulates PH, heat tracing, the leaching precipitation, after an amount of washing of ethanol, drying, detect qualified preparation intermediate B liquid, A liquid includes Radix Isatidis, Herba Artemisiae Scopariae, Ganoderma, Fructus Gardeniae extract; B liquid includes Radix Scutellariae extract;
(1) intermediate A liquid preparation: get Radix Isatidis, Herba Artemisiae Scopariae, Ganoderma, Fructus Gardeniae extract respectively, filter.Add an amount of water for injection, add the 0.1-0.2% active carbon and stir evenly, boil 30 minutes after, filtering decarbonization, add water for injection to the dosing amount, fully mixing was sterilized 45 minutes, and was put cold for 115 ℃, filter,, get filtrate and detect qualified back copulation material usefulness with the ultrafilter ultrafiltration of certain molecular retention amount;
(2) intermediate B liquid preparation: take by weighing Radix Scutellariae extract by the side, add an amount of suspendible of injection water, make dissolving with 10%NaOH solution, transfer PH=7.0-7.5, mixing adds an amount of water for injection, add the 0.1-0.2% active carbon and stir evenly, boil 30 minutes after, use the filter filtering decarbonization, add water for injection to the dosing amount, fully mixing was sterilized 45 minutes, and was put cold for 115 ℃, with the ultrafilter ultrafiltration of certain molecular retention amount, the copulation material is used behind the sample examination content;
(3) get A liquid and B liquid respectively, mix, it is an amount of to add the injection water, regulate medicinal liquid pH7.2-7.9 with 10% sodium hydroxide, [make every 1000ml contain Herba Artemisiae Scopariae extract 4g, Fructus Gardeniae extract 3g, Radix Isatidis extract 5g, Ganoderma extract 3.5g and Radix Scutellariae extract 22g, every 1ml contains Herba Artemisiae Scopariae extract with chlorogenic acid (C to the dosing total amount to add the injection water
16H
18O
9) meter, must not be less than 0.04mg; Contain Fructus Gardeniae extract with jasminoidin (C
17H
24O
10) meter, must not be less than 0.45mg.; Contain Radix Scutellariae extract with baicalin (C
21H
18O
11) meter, must not be less than 19.5mg.Contain total solid and should be 36.0～50.0mg], stir, the medicinal liquid fine straining is extremely clear and bright, embedding, 115 ℃ of 45min sterilizations are promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310103393 CN1186091C (en) | 2002-11-01 | 2003-10-31 | Chinese medicine injection and its production process |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02134005 CN1413730A (en) | 2002-11-01 | 2002-11-01 | Shugan injection and its preparation technology |
| CN02134005.6 | 2002-11-01 | ||
| CN 200310103393 CN1186091C (en) | 2002-11-01 | 2003-10-31 | Chinese medicine injection and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1486743A true CN1486743A (en) | 2004-04-07 |
| CN1186091C CN1186091C (en) | 2005-01-26 |
Family
ID=34523588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310103393 Expired - Lifetime CN1186091C (en) | 2002-11-01 | 2003-10-31 | Chinese medicine injection and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1186091C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813984B (en) * | 2005-12-14 | 2011-08-31 | 贵州瑞和制药有限公司 | Chinese medicine preparation for treating liver disease and preparing method |
| CN105395650A (en) * | 2015-12-09 | 2016-03-16 | 贵州瑞和制药有限公司龙里药厂 | Applications of Shu Gan Ning preparation in preparation of medicines treating osteoporosis and complications of the osteoporosis |
| CN105412295A (en) * | 2015-12-21 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Production process of Shuganning Preparation |
| CN105412291A (en) * | 2015-12-09 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Application of Shuganning to preparation of medicine for treating diabetic neuropathy and complications |
| CN105412294A (en) * | 2015-12-21 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Production method of Shuganning Preparation |
| CN105434342A (en) * | 2015-12-21 | 2016-03-30 | 贵州瑞和制药有限公司龙里药厂 | Preparation method for Shuganning injection preparation |
| CN105878469A (en) * | 2016-05-20 | 2016-08-24 | 贵州瑞和制药有限公司龙里药厂 | Preparation technology of Shuganning injection preparation |
| CN105902488A (en) * | 2016-05-20 | 2016-08-31 | 贵州瑞和制药有限公司龙里药厂 | Process for preparing Shuganning preparation |
-
2003
- 2003-10-31 CN CN 200310103393 patent/CN1186091C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813984B (en) * | 2005-12-14 | 2011-08-31 | 贵州瑞和制药有限公司 | Chinese medicine preparation for treating liver disease and preparing method |
| CN105395650A (en) * | 2015-12-09 | 2016-03-16 | 贵州瑞和制药有限公司龙里药厂 | Applications of Shu Gan Ning preparation in preparation of medicines treating osteoporosis and complications of the osteoporosis |
| CN105412291A (en) * | 2015-12-09 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Application of Shuganning to preparation of medicine for treating diabetic neuropathy and complications |
| CN105412295A (en) * | 2015-12-21 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Production process of Shuganning Preparation |
| CN105412294A (en) * | 2015-12-21 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Production method of Shuganning Preparation |
| CN105434342A (en) * | 2015-12-21 | 2016-03-30 | 贵州瑞和制药有限公司龙里药厂 | Preparation method for Shuganning injection preparation |
| CN105878469A (en) * | 2016-05-20 | 2016-08-24 | 贵州瑞和制药有限公司龙里药厂 | Preparation technology of Shuganning injection preparation |
| CN105902488A (en) * | 2016-05-20 | 2016-08-31 | 贵州瑞和制药有限公司龙里药厂 | Process for preparing Shuganning preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1186091C (en) | 2005-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN101856374A (en) | Anti-aging compound | |
| CN1486743A (en) | Chinese medicine injection and its production process | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN1883582A (en) | Pharmaceutical composition for treating liver disease and method for preparing same | |
| CN1264540C (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN103211996A (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN1056752C (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1778311A (en) | Polysaccharid glucoside Chinese medicinal oral preparation and its making method thereof | |
| CN1265805C (en) | Chinese medicine oral preparation for lonering blood sugar and its preparation method | |
| CN1857378A (en) | Compound wild kiwi tablet and its preparing method | |
| CN1557378A (en) | Medicine for treating diabetes | |
| CN1903276A (en) | Medicinal composition for treating hepatitis B | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN1278698C (en) | Freeze dried injection of seeding of autumnal sowthistle-leaf ixeris and preparation method thereof | |
| CN1957997A (en) | Animal use compound medicament with effects of relieving the muscles and skin, clearing away heat, relieving darrhea, and relieving dysentery, and preparation method | |
| CN1634340A (en) | Medicinal composition for preventing and treating children respiratory system diseases and preparation method thereof | |
| CN1733055A (en) | Fenugreek seed extract and its preparing process and application | |
| CN1170558C (en) | Medicine for treating thrombocytopenia and its application in treating radiation disease | |
| CN1413730A (en) | Shugan injection and its preparation technology | |
| CN1251706C (en) | Prepared traditional Chinese medicine for treating diabetes | |
| CN1435209A (en) | Medicine for treating biabetes and preparing process thereof | |
| CN1284553C (en) | Application of five-finger fig in preparing adjuvant for treating hepatitis and health foods | |
| CN100375632C (en) | Extractive from combined vegetable drug for treating heart disease of coronary sclerosis, and method of extraction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20070927 Pledge (preservation): Pledge |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20090205 Pledge (preservation): Pledge registration |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20090205 Pledge (preservation): Pledge |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20121024 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2009520000514 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine injection and its production process Effective date of registration: 20121024 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000635 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150925 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000635 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine injection and its production process Effective date of registration: 20151008 Granted publication date: 20050126 Pledgee: Agricultural Bank Chinese Limited by Share Ltd. Longli County branch Pledgor: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Registration number: 2015990000842 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| DD01 | Delivery of document by public notice |
Addressee: GUIZHOU RUIHE PHARMACEUTICAL Co.,Ltd. Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xiangqian Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050126 |
|
| CX01 | Expiry of patent term | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Xiangqian Document name: Notice of Termination of Patent Rights |
|
| DD01 | Delivery of document by public notice |